COMP <GO>
RYTM vs ABBV // PIOTROSKI F-SCORE QUALITY
Rhythm Pharmaceuticals Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: RYTM 5
— ABBV 9
▲ PIOTROSKI F-SCORE QUALITY LEADER: ABBV
LAST: $92.57 (-0.54%) • MKT CAP: $6.41B
piotroski-score
5/9
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
piotroski-score
7/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RYTM VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RYTM | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 89.70% | 70.20% | +19.50 | RYTM | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -29.60% | 29.00% | -58.60 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.82% | 3.47% | -5.29 | ABBV | /fcf-yield <GO> |
| Operating Margin | -60.00% | 24.60% | -84.60 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -0.10% | 6.90% | -7.00 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 45.80% | 8.60% | +37.20 | RYTM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 14.33 | 5.33 | +9.00 | RYTM | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 5/9 | 7/9 | -2.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 7.40% | -0.60 | RYTM | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.3 | 72.8 | -22.53 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.96 | 1.15 | -0.19 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 33.0x | 113.1x | -80.10 | RYTM | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $6.41B | $513.86B | -$507.45B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RYTM REV | ABBV REV | RYTM GROSS % | ABBV GROSS % | RYTM FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $189.8M | $61.16B | 89.7% | 70.2% | -$116.6M | $17.82B |
| FY 2024 | $130.1M | $56.33B | 89.7% | 70.0% | -$113.9M | $17.83B |
| FY 2023 | $77.4M | $54.32B | 44.0% | 44.0% | -$139.6M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RYTM // BETA 0.96
ABBV // BETA 1.15